EON is most strongly associated with longer ethambutol duration and renal impairment. The contribution of dosage, hypertension, and diabetes requires further investigation. Overall, judicious planning is required to monitor EON as a potential adverse event of antitubercular therapy.
Gupta et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: